1. Introduction {#sec1}
===============

The thalidomide case in the late 1950s and early 1960s which caused 8000 malformed babies leads to highly consider the safety evaluation of drug use during pregnancy ([@bib55]). However, the focus is currently not only on drugs but also natural products. Some natural products which are commonly consumed, including ginseng, ginger, and ginko biloba, reported to inhibit fetal growth ([@bib34]). Another surprising study by [@bib40] found the administration of green tea increased cyclophosphamide-induced teratogenesis in mice. In addition, fenugreek and asparagus also may retard fetal growth ([@bib23]; [@bib51]).

Propolis is a natural product widely used to support the treatment of some diseases. Propolis is produced by bees from resins and beeswax and plays an important role in colony-level immunity ([@bib4]). Propolis varies greatly in the chemical composition. About 300 chemical compounds have been reported contained in propolis ([@bib27]). However, it is confirmed that propolis has broad spectrum biological activities, including antibacterial, antitumor, antiinflammatory, antifungal, citotoxic, immunomodulatory and antioxidant properties ([@bib32]; [@bib30]; [@bib28]).

Unfortunately, there has no study investigating the effect of propolis administration on fetal development, where its biological activities may affect. The antitumor activity of natural product could inhibit embryonic cells development ([@bib34]), while propolis has been reported to possess that activity ([@bib50]; [@bib38]; [@bib39]; [@bib57]). However, the chemical composition of propolis depends on location, season, bee species, and method of preparation ([@bib44]; [@bib49]). Therefore, this study was aimed to investigate the effect of propolis administration during pregnancy on fetal development in mice for the first time. There were two types of propolis used in the present study, including water extract of propolis from Banten and ethanol extract of propolis from South Sulawesi, Indonesia.

2. Materials and method {#sec2}
=======================

2.1. Sample preparation {#sec2.1}
-----------------------

Raw samples were obtained from CV. Nutrima, Bogor, Indonesia and stored at -5 °C until used. All samples were harvested in 2016. Propolis from Banten was *Mangifera*-type, and propolis from South Sulawesi was *Calophyllum*-type with triterpenes as the main constituent (unpublished data). Samples were prepared with ultrasound-assisted extraction ([@bib54]; [@bib17]). Grounded samples were dissolved in the solvent (water, 75% ethanol) and treated in the ultrasound bath for 4 h. The extracts were filtered and evaporated to obtain dried extracts. The extraction produced water extract of propolis from Banten (WEB) and ethanol extract of propolis from South Sulawesi (EES). Both types of propolis were selected based on our previous result which showed the highest antiemetic activity and potential to use as antiemetic agent for pregnant women ([@bib17]). The extracts were redissolved in 1% Tween 80 as vehicle solution when administering propolis by oral gavage. This vehicle solution has been reported not to cause toxicity ([@bib43]).

2.2. Experimental animals {#sec2.2}
-------------------------

All animal procedures have been approved by the Animal Care and Use Committee, Bogor Agricultural University (No. 64-2017 IPB) and were in accordance with the recommendations of the proper care and use of laboratory animals.

Mice were purchased from The Tropical Biopharmaca Research Centre, Bogor, aged 8--10 weeks and 25--30 g b.wt. The animals were fed with pellet and water *ad libitum* and caged under controlled laboratory condition. To ensure the effectiveness of breeding, estrous cycle was checked using the method of [@bib10] and [@bib9]. Male mice were mated with the female at proestrous and estrous stage on a one-to-one basis. The presence of a vaginal plug on the next day was considered as day 0 of pregnancy. Twenty five pregnant mice were equally allotted to five groups including control group administered with 1% Tween 80 in a dose of 5 ml/kg b.wt., low-dose of WEB group (380 mg/kg b.wt.), high-dose of WEB group (1400 mg/kg b.wt.), low-dose of EES group (380 mg/kg b.wt.), high-dose of EES group (1400 mg/kg b.wt.). Dose of 380 mg/kg b.wt. was active dose as antiemesis according to the previous study after converting it to mice dose ([@bib16]). This was part of big study "The Development of Propolis Candy as Antiemesis in Pregnant Women" and thus we chose antiemesis as the biological activity. In addition, dose of 1400 mg/kg b.wt. was non observed adverse effect level (NOAEL) ([@bib8]). The pregnant mice were administered from 0 until 18 days of gestation to cover embryogenesis, organogenesis, and functional development stages. The weight was measured every two days. The pregnant mice were sacrificed at 18 days of gestation to analyze external and skeletal abnormalities. The placentas were processed to analyze histopathological changes.

2.3. External examination {#sec2.3}
-------------------------

Laparotomy was done to exteriorize the gravid uterus then the amniotic sacs were then carefully opened. Placentas and fetuses were dried and weighed. The number of live fetuses, dead fetuses, and late resorptions were counted. Fetal crown-rump length was measured by taking the picture of each fetus using the stereomicroscope then measured using Java Image J program.

2.4. Histopathological examination of placenta {#sec2.4}
----------------------------------------------

The examination of placenta was done using regular hematoxylin and eosin staining. The procedure was referred to [@bib42]. After removing from the amniotic sac, the samples were fixed in 10% neutral buffered formalin. The samples were dehydrated with alcohol, cleaned with xylene, infiltrated with paraffin, and followed with microtomized section and stained with hematoxylin and eosin.

2.5. Skeletal examination {#sec2.5}
-------------------------

Half of fetus was used for skeletal examination. The fetuses were fixed in 96% ethanol to examine skeletal ossification using Alizarin red S staining. The procedures were referred to [@bib24] with slight modification. Fetuses were eviscerated and soaked in 1% KOH to clear non-calcified tissue. Subsequently, fetuses were stained with 0.01% Alizarin red S solution for 24, drained and destained using 25%, 50%, 75% glycerin in 1% KOH. The specimens were kept in 100% glycerin and observed under the stereomicroscope.

The observation of the fetuses was done by measuring the thickness of the ossification centre using Image J program. The bones measured were sternebrae 5, supraoccipital, forelimb bones (proximal phalanx 2-5, metacarpal 2-5), hindlimb bones (proximal phalanx 1-5, metatarsal 1-5), lumbar 1-6, and caudal 1-6. These bones are sensitive to growth retardation ([@bib18]; [@bib2]).

2.6. Statistical analysis {#sec2.6}
-------------------------

Data were reported as mean ± standard deviation. The difference in external and skeletal examinations between groups was analysed using ANOVA. When there was a significant overall difference between the groups, Tukey\'s post-hoc test was conducted with p-value \<0.05 was considered significant.

3. Result {#sec3}
=========

The external examination of fetuses is presented in [Table 1](#tbl1){ref-type="table"} and illustrated in [Fig. 1](#fig1){ref-type="fig"}. High-dose of WEB and EES significantly decreased the weight of fetuses, but only high-dose of EES significantly decreased the crown-rump length and increased the number of late resorption compared to the control group. There were no significant differences in the number of live fetuses, dead fetuses, pre and post-implantation embryonic loss, and placental weight among all groups.Table 1The effect of propolis administration on the external examination.Table 1ParametersGroupsControl (n = 5)Low-dose of EES (n = 5)High-dose of EES (n = 5)Low-dose of WEB (n = 5)High-dose of WEB (n = 5)Live fetuses8.83 ± 0.9510.20 ± 0.58.86 ± 0.879.40 ± 0.779.00 ± 1.12Fetal weight (g)1.30 ± 0.161.21 ± 0.180.96 ± 0.15[∗](#tbltbl1fnlowast){ref-type="table-fn"}1.36 ± 0.201.03 ± 0.19[∗](#tbltbl1fnlowast){ref-type="table-fn"}Crown-rump length (cm)2.42 ± 0.132.40 ± 0.132.15 ± 0.10[∗](#tbltbl1fnlowast){ref-type="table-fn"}2.54 ± 0.142.27 ± 0.19Placental weight (g)0.12 ± 0.020.12 ± 0.010.12 ± 0.030.11 ± 0.010.13 ± 0.01Dead fetuses0.00 ± 0.00 (0.00%)0.20 ± 0.45 (1.82%)0.57 ± 1.51 (4.08%)0.60 ± 0.55 (5.98%)0.60 ± 1.34 (4.62%)Late resorption0.50 ± 0.55 (6.68%)0.20 ± 0.45 (2.00%)1.33 ± 0.82[∗](#tbltbl1fnlowast){ref-type="table-fn"} (13.17%)0.00 ± 0.00 (0.00%)0.40 ± 0.55 (4.86%)Pre-implantation embryonic loss (%)0.00 ± 0.003.36 ± 4.628.06 ± 11.660.00 ± 0.000.00 ± 0.00Post-implantation embryonic loss (%)6.68 ± 6.403.82 ± 5.2413.17 ± 8.054.99 ± 5.689.47 ± 9.85[^1][^2]Fig. 1The external examination of fetuses. A: control; B: low-dose of EES; C: high-dose of EES; D: low-dose of WEB; E: high-dose of WEB. Lower size was found in high-dose of EES group followed by high-dose of WEB group.Fig. 1

The skeletal examination of fetuses is presented in [Table 2](#tbl2){ref-type="table"}, and illustrated in [Fig. 2](#fig2){ref-type="fig"}. Both low-dose groups did not decrease the thickness of the ossfication centre. High dose of WEB showed relatively lower ossification than control, however, it was not statistically significant. In contrast, high dose of EES significantly decreased the thickness of several ossified bones, including metacarpal 2-4; proximal phalanx 2,3,5 of forelimb; metatarsal 1-5; proximal phalanx of hindlimb 2-5; caudal 6; compared to the control group. In addition, ossified supraoccipital bone showed a lower value than the control group, but not statistically significant. There is an interesting result, where the fetuses in low-dose of WEB group possessed relatively higher weight, crown-rump length, and thickness of ossification centre compared to the other groups.Table 2The thickness of ossified bone of fetuses.Table 2BoneThe thickness (dm)Control (n = 28)Low-dose of EES (28)High-dose of EES (n = 30)Low-dose of WEB (n = 29)High-dose of WEB (n = 28)Sternebrae 50.222 ± 0.040a0.181 ± 0.1010.148 ± 0.0860.237 ± 0.0400.185 ± 0.116Supraoccipital2.980 ± 0.225a,b3.130 ± 0.0612.181 ± 1.1063.202 ± 0.3252.689 ± 0.559Forelimb Metacarpal 20.267 ± 0.043a,b0.271 ± 0.0340.205 ± 0.047[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.304 ± 0.0380.233 ± 0.049 Metacarpal 30.411 ± 0.050a0.407 ± 0.0360.316 ± 0.057[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.410 ± 0.0740.353 ± 0.077 Metacarpal 40.364 ± 0.039a,b0.366 ± 0.0340.278 ± 0.048[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.390 ± 0.0680.319 ± 0.058 Metacarpal 50.144 ± 0.029a,b0.151 ± 0.0200.099 ± 0.0460.176 ± 0.0320.110 ± 0.063 Proximal phalanx 20.105 ± 0.024a0.106 ± 0.0370.042 ± 0.046[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.118 ± 0.0400.074 ± 0.045 Proximal phalanx 30.151 ± 0.041a,b0.143 ± 0.0340.081 ± 0.061[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.181 ± 0.0470.105 ± 0.061 Proximal phalanx 40.153 ± 0.039a,b0.151 ± 0.0350.084 ± 0.0660.177 ± 0.0460.107 ± 0.065 Proximal phalanx 50.094 ± 0.030a0.096 ± 0.0170.035 ± 0.040[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.104 ± 0.0700.053 ± 0.053Lumbar 10.678 ± 0.062a,b0.680 ± 0.0340.646 ± 0.1160.732 ± 0.0980.600 ± 0.090Lumbar 20.697 ± 0.056a0.704 ± 0.0210.661 ± 0.1350.734 ± 0.1050.629 ± 0.100Lumbar 30.693 ± 0.064a0.705 ± 0.0210.669 ± 0.1410.734 ± 0.0810.615 ± 0.096Lumbar 40.643 ± 0.041a0.701 ± 0.0290.631 ± 0.1370.697 ± 0.0780.604 ± 0.117Lumbar 50.601 ± 0.055a0.647 ± 0.0200.578 ± 0.1510.666 ± 0.0770.541 ± 0.126Lumbar 60.563 ± 0.055a0.614 ± 0.0120.528 ± 0.1520.642 ± 0.0810.510 ± 0.121Caudal 10.377 ± 0.055b0.443 ± 0.0390.349 ± 0.1290.525 ± 0.0720.444 ± 0.166Caudal 20.341 ± 0.056a,b0.409 ± 0.0410.283 ± 0.1250.462 ± 0.0780.402 ± 0.179Caudal 30.279 ± 0.075a0.350 ± 0.0240.237 ± 0.1400.388 ± 0.0650.360 ± 0.193Caudal 40.246 ± 0.064a0.293 ± 0.0330.180 ± 0.1530.347 ± 0.0650.320 ± 0.207Caudal 50.194 ± 0.087a,b0.258 ± 0.0410.132 ± 0.1390.311 ± 0.0630.270 ± 0.168Caudal 60.169 ± 0.139a0.156 ± 0.0730.026 ± 0.037[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.268 ± 0.0560.211 ± 0.229Hindlimb Metatarsal 10.110 ± 0.042a0.090 ± 0.0280.043 ± 0.052[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.139 ± 0.0420.083 ± 0.050 Metatarsal 20.442 ± 0.070a,b0.422 ± 0.0570.303 ± 0.080[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.490 ± 0.0630.353 ± 0.097 Metatarsal 30.522 ± 0.070a,b0.504 ± 0.0630.356 ± 0.084[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.550 ± 0.0920.412 ± 0.106 Metatarsal 40.564 ± 0.074a.b0.533 ± 0.0690.393 ± 0.115[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.619 ± 0.0930.459 ± 0.104 Metatarsal 50.388 ± 0.064a,b0.385 ± 0.0430.273 ± 0.082[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.435 ± 0.0680.297 ± 0.089 Proximal phalanx 10.023 ± 0.035b0.008 ± 0.0150.011 ± 0.0290.061 ± 0.039[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.013 ± 0.021 Proximal phalanx 20.078 ± 0.033a0.080 ± 0.0360.024 ± 0.041[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.101 ± 0.0340.055 ± 0.045 Proximal phalanx 30.098 ± 0.042a0.096 ± 0.0420.032 ± 0.049[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.122 ± 0.0390.067 ± 0.053 Proximal phalanx 40.116 ± 0.038a0.110 ± 0.0420.038 ± 0.063[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.133 ± 0.0400.068 ± 0.056 Proximal phalanx 50.094 ± 0.050a0.092 ± 0.0380.001 ± 0.002[∗](#tbltbl2fnlowast){ref-type="table-fn"}0.103 ± 0.0610.044 ± 0.054[^3][^4]Fig. 2The ossification of fetal bones after straining with Alizarin Red S. A: control; B: low-dose of EES; C: high-dose of EES; D: low-dose of WEB; E: high-dose of WEB. High dose of EES significantly reduced the thickness of ossified bones (white arrow), while high-dose of WEB gave moderate impact.Fig. 2

The histopathological examination of placenta is depicted in [Fig. 3](#fig3){ref-type="fig"}. We found a shortened labyrinth of placenta along with the expansion of basal zone in both high-dose groups. Blood vessels formed a short, dense, and highly branched network. The hypertrophy of placenta was also found in several pregnant dams in both high-dose groups.Fig. 3The histopathological examination of placenta. A: control; B: low-dose of EES; C: high-dose of EES; D: low-dose of WEB; E: high-dose of WEB. Small labyrinth along with expansion of basal zone (white arrow) were found in both high-dose groups (bar = 125 μm).Fig. 3

4. Discussion {#sec4}
=============

The present study showed that low-dose of propolis did not cause any alterations in fetal development. However, high-dose of propolis might retard the development. We found decreased fetal weight and crown-rump at high-dose groups. Fetal weight is the main parameter to assess developmental toxicity ([@bib19]; [@bib26]). Moreover, crown-rump is another parameter to examine fetal development and bone maturation ([@bib29]; [@bib26]). This indicates high-dose of propolis could inhibit fetal development.

In addition, high-dose of EES increased the number of late resorption. Mice prefer absorbing the imperfect conception to aborting ([@bib53]). The immunomodulatory property of propolis could be the underlying mechanism. Propolis has been known to possess immunomodulatory property ([@bib36], [@bib37]; [@bib12]; [@bib28]). Resorption may occur due to the rejection via immune system pathway. Increased macrophage activity in the endometrium during pregnancy leads to increased production of NO and TNF-α, which are toxic to embryo development ([@bib3]). Indeed, [@bib52] found colony stimulating factor-1 (CSF-1) might increase resorption in pregnant mice. CSF-1 plays an important role in the differentiation of macrophage.

Anticancer activity of propolis was proposed to be the underlying mechanism of fetal growth retardation in both high-dose groups. It has been known that the anticancer agents are mostly teratogen and vice versa ([@bib6]; [@bib47]; [@bib5]). Some natural products which have anticancer effects are also teratogens. [@bib34] found 6-gingerol (ginger), gingkolide A, gingkolide B (*Gingko biloba*) and gingsennoside Rg1 (ginseng) at high-dose showed teratogenic effects on chick embryonic heart micromass and mouse D3 embryonic stem cell. However, the compounds had no effect at a low dose and it was similar to the present study. Therefore, the teratogenic effect of the natural product might appear only at a high dose.

Anticancer activity of propolis has been extensively examined ([@bib50]; [@bib38]; [@bib39]; [@bib57]). However, there were still few studies reported the anticancer activity of stingless bee propolis and its underlying mechanisms. Stingless bee propolis was reported active to against several cancer cells, including breast, colon, lung, gastric, liver, colorectal, skin, and bone cancer cell lines ([@bib14]; [@bib13]; [@bib31]). Propolis induces TNF-related apoptosis-inducing ligand (TRAIL) which mediates the programming of cell apoptosis ([@bib39]). Propolis also activates caspase cascades and/or inhibit the production of bcl-2 and mitochondrial cytochrome c which lead to apoptosis ([@bib45]).

It is interesting to discuss high-dose of WEB showed a moderate effect of inhibition compared to high dose of EES. However, we did not use raw propolis from the same origin, therefore we cannot compare its effect between the solvents. However, propolis works not as a single constituent but as a mixture ([@bib56]). Regardless of propolis origin, pregnant mice were more tolerated to water extract than ethanol extract. Although there has no study comparing the anticancer activity of water and ethanol extract of propolis, some results of previous studies may help us to explain the findings. Water extraction produces more carbohydrates (sugar) but much less wax and resin than ethanol extract. Vitamins and amino acids coming from bee pollen could probably be extracted ([@bib11]; [@bib35]). This causes the phytochemical content of water extract of propolis less concentrated. It was confirmed by [@bib49] who compared the phytochemical profiles between water and ethanol extract of propolis. In addition, [@bib15] found the major constituents of water extract of propolis were terpenes and carbohydrates. With respect to the theory that natural products induce teratogenic effect at high dose, it is reasonable that water extract was more tolerated than ethanol extract at high dose due to the less concentrated phytochemical composition. This might also explain why did only high-dose of EES increase the number of resorption.

Bone ossification generally reflects the maturity of fetal development ([@bib25]; [@bib22]). This was confirmed by the present study which the fetuses of high-dose of EES group showed lower weight and crown-rump, and retarded bone ossification. Indeed, a high dose of WEB gave moderate effect on the weight and crown-rump length of fetuses and reflected moderate delayed bone ossification. The fetuses of high-dose of EES group seemed to be younger than 18 days of gestation. We found relatively shortened ossification of supraoccipital bone because it mostly had yet to be fused while the fusion should happen at 18 days of gestation ([@bib55]). In addition, high-dose of EES also decreased the thickness of ossification at caudal 6. We found the fetuses in this group mostly had the centre of caudal ossification only up to caudal 5. Moreover, metatarsal 2-4 which the centre of ossification that should appear at 17 days of gestation ([@bib41]) seemed to be more sensitive in detecting delayed ossification. Instead, the bones which should appear later, including metacarpal 5 and some proximal phalanxes tended to have higher variation thus difficult to show a significant result.

The delayed ossification in high-dose groups was not a specific response. Similarly, previous research on developmental toxicity also found the same manner ([@bib46]; [@bib33]; [@bib1]). The delay is due to general fetal growth retardation reflected by lower weight and crown-rump length. In addition, the retardation also followed the cephalocaudal manner, where the variations tend to be common on the hindlimb ([@bib48]).

The inhibition of fetal growth in both high-dose groups might be caused by the disruption of placental development. The small labyrinth is commonly found in the failure of placental development due to the inadequate fabrication of vessels and trophoblast cells ([@bib7]). The trophoblast cells are the most common target by toxicity due to its rapid proliferation ([@bib21]). The small labyrinth and thickening of the basal zone cause the inhibition of nutrient and gas transfer. The hypertrophy of placenta that found in several pregnant dams in both high-dose groups might be the compensatory response of intrauterine growth retardation (IUGR) ([@bib20], [@bib21]).

5. Conclusion {#sec5}
=============

This study concludes that Indonesian propolis at 380 mg/kg b.wt. does not inhibit fetal development. However, Indonesian propolis at 1400 mg/kg b.wt did appear to inhibit fetal development. Non-observed adverse effect level that has been established (1400 mg/kg) cannot be used as the safety level in pregnant condition. Placenta might be the targeted organ of toxicity by propolis that causing the retardation of fetal growth.
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[^1]: High-dose of EES significantly reduced fetal weight and crown-rump length, and increased the number of late resorption. High-dose of WEB significantly reduced only fetal weight. Both low-dose groups did not appear to inhibit fetal growth.

[^2]: Significant in relation to control at p \< 0.05.

[^3]: High-dose of EES significantly delayed the ossification of several bones, including metacarpal 2-3, proximal phalanx 2,3,5 of forelimb, caudal 6, metatarsal 1-5, proximal phalanx 2-5 of hindlimb. High-dose of WEB showed relative inhibition of ossification but not statistically significant compared to control group. However, both low-dose groups did not show any alteration.

[^4]: Significant in relation to control at p \< 0.05; n = number of fetuses.
